Silvr, according to Pfizer's Q2 presentation The Vyndaquel family of products accounted for 6.1% of their revenue and grew revenue by 43% over the previous year.
The LOE for the US is 2024, but they have a Patent Term Extension pending which should take it to 2028. Whereas the EU LOE expires in 2026.
A generic is already approved for FoldRX Pharms. So I imagine they will want to get it approved in the EU in 2025, which gives them time to switch existing patients to the new version.
Silvr, looks like the info regarding Pfizer was a standard template used in coding their webpage. It shows up being blurred for other pharma companies as well.
News 
Market Data 
Discover 
